Rhinostics Inc.

Rhinostics Inc. is an early stage company commercializing a simple and elegant solution to bring efficiencies and cost savings to the laboratory workflow. The RHINOstic nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. 

The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. Additionally, the device allows dry shipment of respiratory samples without viral transport media, and the nasal collection allows for an easy and comfortable collection. Viral samples can be released directly into a small amount of saline, providing sample concentration of 30x or greater, providing greater standardization and improving downstream assay reliability. 

The product provides an immediate impact to increasing COVID testing efficiencies while being applicable to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction (PCR) and next generation sequencing (NGS). 

The RHINOstic product is registered as Class I exempt medical device with the FDA and is available for purchase. To learn more, visit https://www.rhinostics.com.